≡

Eukaryotic Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)

EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT

  • Product No.EPC615Mu61
  • Organism SpeciesMus musculus (Mouse) Same name, Different species.
  • SourceEukaryotic expression
  • Host293F cell
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane, Nucleus, Mitochondrion, Cytoplasm
  • Predicted Molecular Mass19.4kDa
  • Accurate Molecular Mass18kDa(Analysis of differences refer to the manual)
  • Residues & TagsGlu152~Gly308 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 90%
  • Isoelectric Point9.0
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 268  US$ 670  US$ 1340  US$ 4020  US$ 10050 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
ACTA NEUROPATHOLOGICA COMMUNICATIONS Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPC615Mu01 Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Positive Control; Immunogen; SDS-PAGE; WB.
RPC615Mu02 Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Positive Control; Immunogen; SDS-PAGE; WB.
EPC615Mu61 Eukaryotic Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Positive Control; Immunogen; SDS-PAGE; WB.
PAC615Mu01 Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) WB; IHC; ICC/IF;FCM
PAC615Mu02 Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) WB; IHC; ICC; IP.
SEC615Mu ELISA Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC615Mu Multiplex Assay Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.